利妥昔单抗维持治疗降低胰腺胆道IgG4相关疾病复发率
该回顾性研究纳入2005年1月至2015年12月在梅奥诊所接受利妥昔单抗治疗的胰腺胆道IgG4相关疾病患者,比较仅诱导治疗组(14例)与诱导后维持治疗组(29例)的结局。维持治疗组3年复发率11%,低于仅诱导组的45%(P=0.034);感染仅见于维持治疗组(6/43例,P=0.067 vs 仅诱导组)。作者认为维持治疗可延长缓解期,但可能增加感染风险。
要点
- 利妥昔单抗维持治疗组3年复发率11%,低于仅诱导治疗组的45%(P=0.034)。
- 感染见于6/43例患者,全部在维持治疗组(P=0.067 vs 仅诱导组),其中5例发生于维持治疗期间。
- 年轻、诱导后IgG4反应指数评分较高、基线或诱导后碱性磷酸酶升高与复发相关。
核心结论
- 在胰腺胆道IgG4相关疾病的回顾性研究中,利妥昔单抗维持治疗可延长缓解期。
- 接受维持治疗的患者复发不常见,但维持治疗可能增加感染风险。
- 作者认为具有复发预测因素的患者可考虑利妥昔单抗维持治疗。
研究设计与样本
- 回顾性研究,纳入2005年1月至2015年12月在明尼苏达州罗切斯特梅奥诊所接受利妥昔单抗治疗的胰腺胆道IgG4相关疾病患者。
- 队列分为仅接受利妥昔单抗诱导治疗组(第1组,n=14)和诱导后接受维持治疗组(第2组,n=29)。
主要发现
- 第1组中位随访34个月,第2组中位随访27个月(P=0.99)。
- 43例患者中37例(86%)在利妥昔单抗起始后6个月处于无激素缓解。
- 第1组3年复发率为45%,高于第2组的11%(P=0.034)。
- 年轻、诱导治疗后IgG4反应指数评分较高、基线或利妥昔单抗诱导后血清碱性磷酸酶水平升高与复发相关。
- 43例患者中6例发生感染,全部在第2组(P=0.067 vs 第1组),除1例外均发生于维持治疗期间。
临床怎么用
- 作者认为具有复发预测因素的患者可考虑利妥昔单抗维持治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: IgG4-related disease (IgG4-RD), a multi-organ fibroinflammatory syndrome, typically responds to steroids. However, some cases are steroid resistant, and pancreaticobiliary IgG4-RD commonly relapses after steroid withdrawal. Rituximab induces remission of IgG4-RD, but the need for and safety of maintenance rituximab treatment are unknown. We compared outcomes of patients with pancreaticobiliary IgG4-RD treated with or without maintenance rituximab therapy. METHODS: We performed a retrospective study of patients with pancreaticobiliary IgG4-RD treated with rituximab at the Mayo Clinic in Rochester, Minnesota, from January 2005 through December 2015. The cohort was divided into patients who received only rituximab induction therapy (group 1, n = 14) and patients who received rituximab induction followed by maintenance therapy (group 2, n = 29). We collected data on recurrence of IgG4-RD symptoms and findings, as well as information on evaluations, treatment, and adverse events. RESULTS: Median follow-up times were similar between group 1 (34 mo) and group 2 (27 mo) (P = .99). Thirty-seven patients (86%) were in steroid-free remission 6 months after rituximab initiation. A higher proportion of patients in group 1 had disease relapse (3-year event rate, 45%) than in group 2 (3-year event rate, 11%) (P = .034). Younger age, higher IgG4 responder index score after induction therapy, and increased serum levels of alkaline phosphatase at baseline or after rituximab induction were associated with relapse. Infections developed in 6 of 43 patients, all in group 2 (P = .067 vs group 1); all but 1 occurred during maintenance therapy. CONCLUSIONS: In a retrospective study of patients with pancreaticobiliary IgG4-RD, we found rituximab maintenance therapy prolongs remission. Relapses are uncommon among patients receiving maintenance therapy, but maintenance therapy may increase risk of infection. Patients with factors that predict relapse could be candidates for rituximab maintenance therapy.
引用
- Majumder S, Mohapatra S, Lennon RJ, et al. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease. Clin Gastroenterol Hepatol. 2018. PMID: 29526692. doi:10.1016/j.cgh.2018.02.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。